Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted 01 June, 2011 and appeared in  MedicationType 2 DiabetesIssue 576GLP-1 Series Issue 1GLP-1 Series Issue 3GLP-1 Series Issue 4GLP-1 Series Issue 5GLP-1

Sanofi's Once Daily GLP-1 Lyxumia ® Meets Primary Endpoint in Phase 3 Study

Lyxumia (lixisenatide) when used as an add-on therapy to basal insulin (in association with or without metformin), achieved its primary efficacy endpoint of significantly reducing HbA1c versus placebo for patients with type 2 diabetes without significantly increasing their risk of hypoglycemia....

Advertisement

Sanofi announced that its GetGoal-L is one of nine studies in the GetGoal phase III clinical program, and the second trial to investigate the benefits of lixisenatide 20µg once-daily combined with basal insulin. It was a randomized (double-blind), placebo-controlled study with a 24-week main treatment period, and a total of 495 patients received either lixisenatide or placebo.

GetGoal-L showed a significant reduction in HbA1c levels (p=0.0002) with lixisenatide, without a significant increase in the incidence of symptomatic hypoglycemia (p=0.14) versus placebo. In addition, patients treated with lixisenatide had significantly improved postprandial plasma glucose after a test meal (p<0.0001). Patients in the lixisenatide arm of the study also reported a significant reduction in body weight (p<0.0001). These results confirm those previously reported on GetGoal-L Asia, this time in a broader population including both Caucasian and Asian patients. As expected with a GLP-1, the most commonly reported adverse event with lixisenatide was nausea with a low rate of discontinuation.

"These positive efficacy and safety results are another important milestone in the GetGoal clinical trial program and show the potential value of adding Lyxumia (lixisenatide) to basal insulin to improve glycemic control," said Pierre Chancel, senior vice president, Global Diabetes Division at Sanofi. "The findings from this and previous studies reinforce a continuing positive trend demonstrating the potential of lixisenatide to improve the lives of people with type 2 diabetes."

The full study results from GetGoal-L are planned to be presented at a medical congress.

Lixisenatide, a Glucagon-Like Peptide-1 agonist (GLP-1), is in development for the treatment of patients with type 2 diabetes mellitus. Lixisenatide was in-licensed from Zealand Pharma A/S (Copenhagen, Denmark).

The GetGoal phase III clinical program will provide data for the efficacy and safety of lixisenatide in adults with type 2 diabetes treated with various oral anti-diabetic agents or insulin. With nine trials in the program, GetGoal started in May 2008 and has enrolled more than 4300 patients. To date GetGoal-X, GetGoal-Mono, GetGoal-L Asia and GetGoal-S have reported positive top-line results supporting efficacy and safety for lixisenatide. Further results are expected during 2011.

Sanofi News Release June, 2011

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 01 June, 2011 and appeared in  MedicationType 2 DiabetesIssue 576GLP-1 Series Issue 1GLP-1 Series Issue 3GLP-1 Series Issue 4GLP-1 Series Issue 5GLP-1

Past five issues: Diabetes Clinical Mastery Series Issue 206 | SGLT-2 Inhibitors Special Edition September 2014 | Issue 746 | Diabetes Clinical Mastery Series Issue 205 | Humulin Insulin Special Edition September 2014 |

2014 Most Popular Articles:

Diabetic Neuropathy Improved with Vegan Diet
Posted August 22, 2014
Abbott Announces Approval of Its New Unique Continuous Glucose Monitor
Posted September 05, 2014
CDC: 40% of American Adults Will Develop Diabetes
Posted August 22, 2014
Low Carb Beats Low Fat
Posted September 05, 2014
Empagliflozin (Jardiance) SGLT-2 Inhibitor Now Available in Pharmacies
Posted August 29, 2014
FDA Approves J&J's Invokamet Combo (SGLT-2 + Metformin)
Posted August 15, 2014
New Ultra-Rapid-Acting Insulin Formulation
Posted August 22, 2014
Pistachios Associated with an Improved Metabolic Risk Profile in Prediabetes
Posted August 29, 2014
Lilly's Basal Insulin Peglispro Demonstrated HbA1c Superiority against Lantus
Posted September 05, 2014
Sensor Implant Measures Blood pH in Type 1 Diabetes
Posted August 29, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Diabetes in Control is considering launching a store tab on the site with the ability to purchase A1C tests and other diagnostic test in bulk for medical professionals. What do you think?
CME/CE of the Week
John Steinberg, DPM

Category: Wound Care
Credits: .5


Advertisement


Search Articles On Diabetes In Control